Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 4c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.42), $0.04 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $10.89 million versus the consensus estimate of $19.9 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• MP Materials seen largely insulated after China export-control move